Immunology and Microbiology
Cyclophosphamide
100%
Graft-Versus-Host Disease
63%
Transplant Procedure
53%
Bone Marrow Transplantation
47%
Conditioning
31%
T Cell
31%
Drug Megadose
28%
Overall Survival
22%
Human Leukocyte Antigen
15%
Chronic Graft Versus Host Disease
14%
Lymphocyte
14%
Engraftment
14%
Hematopoietic Cell
13%
Acute Graft Versus Host Disease
13%
Progression Free Survival
13%
Umbilical Cord Blood
13%
Cell Transplantation
12%
Myeloid
12%
Stem Cell Transplantation
12%
Chimera
11%
Allogeneic Bone Marrow Transplantation
9%
Allotransplantation
9%
Event Free Survival
7%
Recurrence Free Survival
7%
Allotransplantation
6%
Mouse
6%
Immunosuppression
6%
Hematopoietic Stem Cell Transplantation
6%
Cord Blood Stem Cell Transplantation
5%
Sickle Cell
5%
B Cell
5%
Mycophenolic Acid
5%
Alloimmunity
5%
Keyphrases
Post-transplantation Cyclophosphamide (PTCy)
68%
Graft-versus-host Disease (GvHD)
45%
Haploidentical Transplantation
38%
HLA-haploidentical
27%
Nonmyeloablative
19%
Hematological Malignancies
18%
HLA Matching
17%
Confidence Interval
16%
Haploidentical
16%
Allogeneic Blood or Marrow Transplantation
15%
Transplantation
15%
Bone Marrow Transplantation
14%
Graft-versus-host Disease Prophylaxis
14%
Blood or Marrow Transplantation
13%
Allogeneic Bone Marrow Transplantation
13%
Haploidentical Donor
13%
Overall Survival
13%
Human Leukocyte Antigen
13%
High Dose
12%
Hazard Ratio
11%
Non-relapse Mortality
11%
Reduced-intensity Conditioning
11%
Marrow Transplantation
10%
Donor Lymphocyte Infusion
9%
Unrelated Donor
9%
Allogeneic Transplantation
8%
Cyclophosphamide
8%
Myeloablative Conditioning
8%
Myeloablative
8%
Cumulative Incidence
8%
Bone Marrow
7%
HLA-matched Donor
7%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
7%
Acute Myeloid Leukemia
6%
Event-free Survival
6%
Pretransplant
6%
Progression-free Survival
6%
Mismatched Related Donor
6%
Haploidentical Hematopoietic Stem Cell Transplantation
6%
High-dose Cyclophosphamide
6%
High Risk
5%
Graft Failure
5%
Acute Leukemia
5%
Peripheral Blood
5%
Relapse-free Survival
5%
Acute Lymphoblastic Leukemia
5%
Immunosuppression
5%
Lymphoma
5%
Medicine and Dentistry
Cyclophosphamide
47%
Graft Versus Host Reaction
33%
Transplantation
23%
Bone Marrow Transplantation
22%
T Cell
21%
Hematologic Malignancy
17%
Disease
15%
Prophylaxis
14%
Drug Megadose
13%
Overall Survival
12%
Cumulative Incidence
9%
Donor Lymphocyte Infusion
9%
Acute Myeloid Leukemia
8%
Graft Failure
8%
Chronic Graft Versus Host Disease
7%
Nonmyeloablative Conditioning
7%
Allogenic Bone Marrow Transplantation
7%
Malignant Neoplasm
7%
Whole Body Radiation
6%
Immunotherapy
6%
Event Free Survival
6%
Progression Free Survival
6%
Stem Cell Therapy
6%
Acute Graft Versus Host Disease
5%
Cell Transplantation
5%
Hematopoietic Stem Cell
5%
Engraftment
5%
Immunosuppressive Treatment
5%
Allotransplantation
5%
Haploidentical Transplantation
5%